Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Down 85.5% in August

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 29,679 shares, a decline of 85.5% from the July 30th total of 205,218 shares. Based on an average daily volume of 85,940 shares, the days-to-cover ratio is presently 0.3 days. Approximately 6.3% of the company’s stock are sold short.

Hedge Funds Weigh In On Jupiter Neurosciences

Hedge funds have recently modified their holdings of the stock. Vestor Capital LLC increased its position in shares of Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after acquiring an additional 970,314 shares during the last quarter. Geode Capital Management LLC boosted its position in Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the last quarter. Yorkville Advisors Global LP bought a new position in Jupiter Neurosciences in the fourth quarter valued at approximately $135,000. Finally, Allen Capital Group LLC acquired a new position in shares of Jupiter Neurosciences during the 4th quarter worth approximately $31,000.

Wall Street Analyst Weigh In

JUNS has been the topic of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. Wall Street Zen raised shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Jupiter Neurosciences Trading Down 1.8%

Shares of NASDAQ JUNS traded down $0.10 during midday trading on Wednesday, reaching $5.08. The company’s stock had a trading volume of 192,430 shares, compared to its average volume of 406,862. The stock has a 50 day simple moving average of $11.23 and a 200-day simple moving average of $22.97. The stock has a market capitalization of $3.91 million, a price-to-earnings ratio of -0.27 and a beta of 1.98. Jupiter Neurosciences has a fifty-two week low of $4.56 and a fifty-two week high of $137.96.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its earnings results on Friday, August 14th. The company reported ($5.06) EPS for the quarter, missing the consensus estimate of ($3.75) by ($1.31). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.40 million.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.